BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BRM - US1101221083 - Common Stock
43.35 EUR
-0.27 (-0.61%)
Taking everything into account, BRM scores 6 out of 10 in our fundamental rating. BRM was compared to 54 industry peers in the Pharmaceuticals industry. BRM has only an average score on both its financial health and profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on BRM. BRM also has an excellent dividend rating. With these ratings, BRM could be worth investigating further for value and dividend investing!.
1. Profitability
1.1 Basic Checks
In the past year BRM was profitable.
BRM had a positive operating cash flow in the past year.
In multiple years BRM reported negative net income over the last 5 years.
BRM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BRM has a Return On Assets (6.23%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of 32.55%, BRM belongs to the top of the industry, outperforming 81.48% of the companies in the same industry.
BRM has a better Return On Invested Capital (16.42%) than 79.63% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BRM is below the industry average of 13.89%.
The 3 year average ROIC (10.96%) for BRM is below the current ROIC(16.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 16.42% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
With a Profit Margin value of 12.57%, BRM perfoms like the industry average, outperforming 51.85% of the companies in the same industry.
BRM has a Operating Margin of 33.51%. This is amongst the best in the industry. BRM outperforms 85.19% of its industry peers.
BRM's Operating Margin has declined in the last couple of years.
BRM's Gross Margin of 73.15% is fine compared to the rest of the industry. BRM outperforms 61.11% of its industry peers.
BRM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
BRM has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, BRM has less shares outstanding
Compared to 5 years ago, BRM has less shares outstanding
The debt/assets ratio for BRM is higher compared to a year ago.
2.2 Solvency
BRM has an Altman-Z score of 2.18. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
BRM has a Altman-Z score of 2.18. This is in the lower half of the industry: BRM underperforms 61.11% of its industry peers.
The Debt to FCF ratio of BRM is 3.20, which is a good value as it means it would take BRM, 3.20 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BRM (3.20) is better than 61.11% of its industry peers.
A Debt/Equity ratio of 2.41 is on the high side and indicates that BRM has dependencies on debt financing.
BRM's Debt to Equity ratio of 2.41 is on the low side compared to the rest of the industry. BRM is outperformed by 79.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.18 |
ROIC/WACC1.99
WACC8.27%
2.3 Liquidity
BRM has a Current Ratio of 1.27. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BRM (1.27) is worse than 64.81% of its industry peers.
BRM has a Quick Ratio of 1.17. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
BRM has a better Quick ratio (1.17) than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 460.68% over the past year.
BRM shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.57% yearly.
Looking at the last year, BRM shows a small growth in Revenue. The Revenue has grown by 1.26% in the last year.
BRM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.06% yearly.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
3.2 Future
BRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.26% yearly.
The Revenue is expected to decrease by -4.97% on average over the next years.
EPS Next Y479.55%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
EPS Next 5Y35.26%
Revenue Next Year0.19%
Revenue Next 2Y-4.06%
Revenue Next 3Y-3.05%
Revenue Next 5Y-4.97%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 7.69, the valuation of BRM can be described as very cheap.
92.59% of the companies in the same industry are more expensive than BRM, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.29, BRM is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 8.28, the valuation of BRM can be described as reasonable.
Based on the Price/Forward Earnings ratio, BRM is valued cheaper than 87.04% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.51, BRM is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.69 | ||
| Fwd PE | 8.28 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BRM is valued cheaply inside the industry as 88.89% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, BRM is valued cheaply inside the industry as 98.15% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.71 | ||
| EV/EBITDA | 6.41 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BRM has a very decent profitability rating, which may justify a higher PE ratio.
BRM's earnings are expected to grow with 73.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y131.22%
EPS Next 3Y73.98%
5. Dividend
5.1 Amount
BRM has a Yearly Dividend Yield of 4.77%, which is a nice return.
Compared to an average industry Dividend Yield of 2.90, BRM pays a better dividend. On top of this BRM pays more dividend than 90.74% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.31, BRM pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.77% |
5.2 History
The dividend of BRM is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
82.81% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
The dividend of BRM is growing, but earnings are growing more, so the dividend growth is sustainable.
DP82.81%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
FRA:BRM (12/10/2025, 10:25:48 AM)
43.35
-0.27 (-0.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners81.74%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap88.25B
Revenue(TTM)48.03B
Net Income(TTM)6.04B
Analysts67.65
Price Target45.88 (5.84%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.77% |
Yearly Dividend2.07
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)0.77%
PT rev (3m)1.52%
EPS NQ rev (1m)-0.47%
EPS NQ rev (3m)4.49%
EPS NY rev (1m)1.22%
EPS NY rev (3m)0.41%
Revenue NQ rev (1m)-0.24%
Revenue NQ rev (3m)2.19%
Revenue NY rev (1m)0.53%
Revenue NY rev (3m)1.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.69 | ||
| Fwd PE | 8.28 | ||
| P/S | 2.14 | ||
| P/FCF | 6.71 | ||
| P/OCF | 6.18 | ||
| P/B | 5.54 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.41 |
EPS(TTM)5.64
EY13.01%
EPS(NY)5.24
Fwd EY12.08%
FCF(TTM)6.46
FCFY14.9%
OCF(TTM)7.02
OCFY16.18%
SpS20.28
BVpS7.83
TBVpS-9.99
PEG (NY)0.02
PEG (5Y)N/A
Graham Number31.52
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 16.42% | ||
| ROICexc | 21.58% | ||
| ROICexgc | 109.99% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.18 |
F-Score6
WACC8.27%
ROIC/WACC1.99
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y479.55%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
EPS Next 5Y35.26%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year0.19%
Revenue Next 2Y-4.06%
Revenue Next 3Y-3.05%
Revenue Next 5Y-4.97%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year262.1%
EBIT Next 3Y50.55%
EBIT Next 5Y23.19%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 6 / 10 to BRM.DE.
What is the valuation status for BRM stock?
ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 6 / 10.
How financially healthy is BRISTOL-MYERS SQUIBB CO?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 5 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to grow by 479.55% in the next year.